- Home
- JHS vs GALT Comparison
JHS vs GALT Comparison
Compare JHS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JHS
- GALT
- Stock Information
- Founded
- JHS 1973
- GALT 2000
- Country
- JHS United States
- GALT United States
- Employees
- JHS N/A
- GALT N/A
- Industry
- JHS Finance Companies
- GALT Biotechnology: Pharmaceutical Preparations
- Sector
- JHS Finance
- GALT Health Care
- Exchange
- JHS Nasdaq
- GALT Nasdaq
- Market Cap
- JHS 135.2M
- GALT 147.8M
- IPO Year
- JHS N/A
- GALT N/A
- Fundamental
- Price
- JHS $11.34
- GALT $2.08
- Analyst Decision
- JHS
- GALT Strong Buy
- Analyst Count
- JHS 0
- GALT 1
- Target Price
- JHS N/A
- GALT $11.00
- AVG Volume (30 Days)
- JHS 32.8K
- GALT 549.5K
- Earning Date
- JHS 01-01-0001
- GALT 11-13-2024
- Dividend Yield
- JHS 3.96%
- GALT N/A
- EPS Growth
- JHS N/A
- GALT N/A
- EPS
- JHS 0.02
- GALT N/A
- Revenue
- JHS N/A
- GALT N/A
- Revenue This Year
- JHS N/A
- GALT N/A
- Revenue Next Year
- JHS N/A
- GALT N/A
- P/E Ratio
- JHS $553.50
- GALT N/A
- Revenue Growth
- JHS N/A
- GALT N/A
- 52 Week Low
- JHS $9.76
- GALT $1.56
- 52 Week High
- JHS $11.25
- GALT $4.27
- Technical
- Relative Strength Index (RSI)
- JHS 35.76
- GALT 38.64
- Support Level
- JHS $11.36
- GALT $1.99
- Resistance Level
- JHS $11.47
- GALT $2.36
- Average True Range (ATR)
- JHS 0.08
- GALT 0.22
- MACD
- JHS -0.03
- GALT -0.02
- Stochastic Oscillator
- JHS 0.00
- GALT 24.14
About JHS John Hancock Income Securities Trust
John Hancock Income Securities Trust is a United States-based closed-ended diversified management investment company. Its primary objective is to generate a high level of current income consistent with prudent investment risk. The fund invests its net assets (plus borrowings for investment purposes) in income securities, consisting of marketable corporate debt securities, governmental obligations, and cash & commercial paper.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.